Moderna, Inc. (MRNA) has a MarketKingdoms composite score of 58.1 (B-), an B-range rating. It ranks 1433rd of 1,866 covered companies, 71st of 78 in Healthcare (sector average 64.4) and 10th of 12 in Biotechnology. Scores as of 2026-10-26.
Its strongest lenses are KPI momentum at 87 (Healthcare average 78) and Trend (momentum) at 85 (Healthcare average 50). Its weakest lenses are Quality (profitability) at 3 (sector average 50) and Price (valuation) at 3 (sector average 50).
| Lens | Type | MRNA | Healthcare average | Biotechnology average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 77 | 81 | 77 | 44th |
| Stock selection | Research signal | 84 | 79 | 78 | 78th |
| KPI momentum | Research signal | 87 | 78 | 75 | 78th |
| Catalyst watch | Research signal | 81 | 74 | 74 | 97th |
| Price (valuation) | Fundamental lens | 3 | 50 | 30 | 3rd |
| Expansion (growth) | Fundamental lens | 44 | 50 | 64 | 44th |
| Quality (profitability) | Fundamental lens | 3 | 50 | 55 | 3rd |
| Trend (momentum) | Fundamental lens | 85 | 50 | 48 | 95th |
The most recent call analysed was held on 2026-07-31 (fiscal 2026 Q2). MarketKingdoms checks what management promised on each call against what it later delivered.
The stock's valuation gap is +170.9%: its price is well above the path its market, sector and industry moves explain (the model reads it as strongly overvalued versus that path). Factor sensitivity: market beta 10.86, sector beta 3.82, industry beta 6.07; the factor model explains 26% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| Royalty Pharma plc (RPRX) | 74.9 | B+ | -17.8% |
| BeOne Medicines Ltd ADR (ONC) | 73.4 | B+ | -26.6% |
| Regeneron Pharmaceuticals Inc. (REGN) | 72.7 | B+ | +7.7% |
| Vertex Pharmaceuticals Incorporated (VRTX) | 68.1 | B | -7.5% |
| argenx SE ADR (ARGX) | 68.0 | B | -27.3% |
| Incyte Corporation (INCY) | 68.0 | B | -18.8% |
| Alnylam Pharmaceuticals Inc. (ALNY) | 61.4 | B- | -18.1% |
| Bio-Techne Corporation (TECH) | 60.4 | B- | -22.2% |
Moderna, Inc. financial statements · Healthcare sector ranking · Biotechnology industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.